Novartis India Limited (500672) fair value: what the stock is really worth
As of Nov 2, 2026: fair value (intrinsic value) of Novartis India Limited stock ₹308, price ₹1,718, that is 82.1% below the price, quality 74 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Novartis India Limited
500672 · BSEFar too expensive (fair value 82% below the price), but solid company and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range ₹527.05 – ₹2,425 · fair‑value band ₹211.06 – ₹401.94 · the ₹1,718 price screens above the ₹308.10 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Every Wednesday you see whether Novartis India is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Novartis India Limited manufactures and sells healthcare products in India and internationally.
Show moreShow less
The company offers a portfolio of prescription medicines in the areas of bone and pain, calcium portfolio, gynecology and neurosciences, oncology, primary care, and specialty medicines through healthcare professionals.
It also provides generics products primarily focused on the therapeutic segments, such as anti-TB, anti-DUB, antihistamines, oncology, injectables, antibiotics, anti-ulcerants, anti-diabetes, and cardiovascular. In addition, the company offers eye care products.
The company was founded in 1947 and is based in Mumbai, India. Novartis India Limited is a subsidiary of Novartis AG.
Stock analysis
Novartis India Limited (500672) currently trades at ₹1,718, while our model-based Fair Value estimate is ₹308.10, 82% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹627.07 per share, and 0 of the 24 models we run sit above the ₹1,718 price.
Bear case: the Dividend Discount group reads lowest at ₹157.96, and 24 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹211.06 (bear) to ₹401.94 (bull), the price of ₹1,718 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Novartis India Limited reported revenue of ₹3.5B in FY2026 versus ₹4.0B in FY2022, a compound −3.0%/yr. Reported net income was ₹932M in FY2026.
Key figures
Market cap ₹15.2B (≈ $162M) Micro · P/E ratio 151.8 · P/S ratio 39.9 · EPS (TTM) ₹4.06 · Dividend yield 4.1% · Net margin 26.3% · Return on assets (EBIT) 5.7% (5-year average) · Free cash flow ₹464M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 79 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 126% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −82%, 500672 screens richer than that median.
Fair Value models
All 24 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
500672 screens overvalued: fair value 82% below the price. Compare with Merck KGaA →
Compare Novartis India Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on equity by industry
- Quality Score by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $84.39 | $113.53 | +35% | vs 500672 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs 500672 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs 500672 |
| Haleon plc HLN | $9.20 | $8.47 | −8% | vs 500672 |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs 500672 |
| Galderma Group GALD | CHF 191.00 | CHF 112.46 | −41% | vs 500672 |
| Takeda Pharmaceutical Company TAK | $21.59 | $11.23 | −48% | vs 500672 |
| Teva Pharmaceutical Industries Limited TEVA | $42.57 | $20.74 | −51% | vs 500672 |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs 500672 |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs 500672 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Novartis India Limited (500672) overvalued or undervalued?
What is the fair value of 500672?
What is the quality score of 500672?
What is the price target for Novartis India Limited (500672)?
What is the Novartis India Limited stock forecast for 2026?
Does Novartis India Limited pay a dividend?
How much is the dividend of Novartis India Limited (500672)?
What growth is priced into Novartis India Limited (500672)?
What discount rate (WACC) does the fair value of 500672 use?
What is a reverse DCF?
How much growth has Novartis India Limited (500672) delivered so far?
How fast is the sector of Novartis India Limited (500672) growing?
What is the free cash flow yield of Novartis India Limited (500672)?
What is the intrinsic value of Novartis India Limited (500672)?
Is Novartis India Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 500672?
How much is Novartis India Limited worth?
What do the bullish and bearish scenarios say about 500672?
What is the P/E ratio of 500672?
How far is 500672 from its 52-week high?
Which stocks are comparable to Novartis India Limited?
Is Novartis India Limited stock attractive at the current price?
How is the fair value of 500672 calculated?
Is it still worth investing in stocks now?
What is the share price of Novartis India Limited (500672)?
What should I pay attention to with Novartis India Limited right now?
Key figures of Novartis India Limited
How large is the market capitalisation of Novartis India Limited (500672)?
What is the P/S ratio of Novartis India Limited (500672)?
What are the earnings per share of Novartis India Limited (500672)?
What is the dividend yield of Novartis India Limited (500672)?
What is the net margin of Novartis India Limited (500672)?
What is the EBIT return on assets of Novartis India Limited (500672)?
Watch Novartis India Limited in the live analysis
One click puts Novartis India Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.